SCYNEXIS Initiates Dosing in Phase 1 Trial of SCY-247, a Second-Generation Fungerp Candidate for Invasive Fungal Infections

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read More Add to Saved list
  • Source:
    Pharma & Healthcare Monitor Worldwide (Amman, Jordan), December 19, 2024 News, 3pp
  • Additional Information
    • Abstract:
      (GlobeNewswire) - SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced that it has completed the dosing of the first cohort of subjects in its Phase 1 trial of SCY-247, the Companys second-generation triterpenoid antifungal in development for the treatment of severe invasive fungal infections...